{"prompt": "['investigators should be completed and submitted to the Sponsor or its designee immediately', '(i.e., no more than 24 hours after learning of the event), either by faxing or by scanning and', 'emailing the form using the fax number or email address provided to investigators.', '5.4.2.2', 'Events That Occur after Study Drug Initiation', 'After initiation of study drug and until 28 days from the last study treatment dose all SAEs', 'and AEs of special interest will be reported.', 'After 28 days from the last study treatment, SAEs related to study treatment and all AEs of', 'special interest will be reported until 7 months after the last study treatment. Additional', 'events that will be reported during this period are described in Section 5.3.1.', 'After seven months from the last study treatment until the end of the study, SAEs related to', 'study treatment will be reported. Additional events that will be reported during this period are', 'described in Section 5.6.', 'Investigators should record all case details that can be gathered immediately (i.e., within 24', 'hours after learning of the event) on the Adverse Event eCRF and submit the report via the', 'electronic data capture (EDC) system. A report will be generated and sent to Roche Safety', 'Risk Management by the EDC system.', 'In the event that the EDC system is unavailable, the paper Clinical Trial Serious Adverse', 'Event / Adverse Event of special interest Reporting Form provided to investigators should be', 'completed and submitted to the Sponsor or its designee immediately (i.e., no more than 24', 'hours after learning of the event), either by faxing or by scanning and emailing the form', 'using the fax number or email address provided to investigators. Once the EDC system is', 'available, all information will need to be entered and submitted via the EDC system.', 'Instructions for reporting SAEs that occur after the end of the study are provided in Section', '5.6.', '5.4.3', 'Reporting Requirements for Pregnancies', 'In addition to the reporting requirements described below, other information will be', 'requested by Roche / Genentech Drug Safety in order to learn more about the effects of', 'pertuzumab and trastuzumab on pregnancy. This information will be requested on any', 'pregnancy or infant exposed to Perjeta IV, Herceptin IV or pertuzumab and trastuzumab', 'FDC SC at specific time points (i.e., after having received the initial report during the first', 'trimester, at the end of the second trimester, 2 weeks after the expected date of delivery,', \"and at 3, 6, and 12 months of the infant's life). In case of a report of congenital abnormality,\", 'a guided questionnaire will be sent out by Roche / Genentech Drug Safety.', '5.4.3.1', 'Pregnancies in Female Patients', 'Female patients of childbearing potential will be instructed to immediately inform the', 'investigator if they become pregnant during the study or within seven months after the final', 'dose of study drug. A paper Clinical Trial Pregnancy Reporting Form should be completed', 'and submitted to the Sponsor or its designee immediately (i.e., no more than 24 hours after', 'learning of the pregnancy), either by faxing or by scanning and emailing the form using the', 'fax number or email address provided to investigators. Pregnancy should not be recorded', 'on the Adverse Event eCRF. The investigator should discontinue study drug and counsel', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '77 / Protocol MO40628, Version 12']['the patient, discussing the risks of the pregnancy and the possible effects on the foetus.', 'Monitoring of the patient should continue until conclusion of the pregnancy. Any SAEs', 'associated with the pregnancy (e.g., an event in the foetus, an event in the mother during or', 'after the pregnancy, or a congenital anomaly / birth defect in the child) should be reported on', 'the Adverse Event eCRF. In addition, the investigator will submit a Clinical Trial Pregnancy', 'Reporting Form when updated information on the course and outcome of the pregnancy', 'becomes available.', '5.4.3.2', 'Pregnancies in Female Partners of Male Patients', 'Male patients will be instructed through the Informed Consent Form to immediately inform', 'the investigator if their partner becomes pregnant during the study or within seven months', 'after the final dose of study drug. A paper Clinical Trial Pregnancy Reporting Form should', 'be completed and submitted to the Sponsor or its designee immediately (i.e., no more than', '24 hours after learning of the pregnancy), either by faxing or by scanning and emailing the', 'form using the fax number or email address provided to investigators. Attempts should be', 'made to collect and report details of the course and outcome of any pregnancy in the partner', 'of a male patient exposed to study drug. When permitted by the site, the pregnant partner', 'would need to sign an Authorization for Use and Disclosure of Pregnancy Health Information', 'to allow for follow-up on her pregnancy. If the authorization has been signed, the', 'investigator should submit a Clinical Trial Pregnancy Reporting Form when updated', 'information on the course and outcome of the pregnancy becomes available. An', 'investigator who is contacted by the male patient or his pregnant partner may provide', 'information on the risks of the pregnancy and the possible effects on the foetus, to support', 'an informed decision in cooperation with the treating physician and/or obstetrician.', '5.4.3.3', 'Abortions', 'Any abortion should be classified as an SAE (as the Sponsor considers abortions to be', 'medically significant), recorded on the Adverse Event eCRF, and reported to the Sponsor', 'immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).', '5.4.3.4', 'Congenital Anomalies / Birth Defects', 'Any congenital anomaly / birth defect in a child born to a female patient exposed to study', 'drug or the female partner of a male patient exposed to study drug should be classified as', 'an SAE, recorded on the Adverse Event eCRF, and reported to the Sponsor immediately', '(i.e., no more than 24 hours after learning of the event; see Section 5.4.2).', '5.4.4', 'Reporting Requirements for Cases of Accidental Overdose or', 'Medication Error', 'Accidental overdose and medication error (hereafter collectively referred to as \"special', 'situations), are defined as follows:', 'Accidental overdose: accidental administration of a drug in a quantity that is higher than', 'the assigned dose', 'Medication error: accidental deviation in the administration of a drug', 'In some cases, a medication error may be intercepted prior to administration of the drug.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '78 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}